Register update: there will be a delay adding new records during our holiday period (Dec 17 - Jan 4)
Cochrane COVID-19 Study Register
Study record
ChiCTR2100051688First Published: 2022 Jan 28Updated Date: 2022 Jan 28

Clinical Study on the Combined Application of Hymecromone Tablets in the Treatment of SARS-CoV-2 Infection

  1. Study Type
  2. Other
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
Reference record

Clinical Study on the Combined Application of Hymecromone Tablets in the Treatment of SARS-CoV-2 Infection

ChiCTR2100051688
Trial registry record
No Results
INTERVENTION: conventional treatment group:conventional treatment; conventional treatment combined with hymecromone tablets group: conventional treatment combined with hymecromone tablets treatment; CONDITION: Novel Coronavirus Pneumonia (COVID-19) PRIMARY OUTCOME: Hyaluronic acid; Virus negative time; SECONDARY OUTCOME: CD44 factor; VII factor activity;uPA / uPAR dynamic change; INCLUSION CRITERIA: All inclusion criteria must be met to qualify for inclusion: 1. The age should be over 18 years old and under 70 years old, with no gender limit. Those who meet the diagnostic criteria of clinical pneumonia 2. According to the clinical diagnosis of viral pneumonia: (1) Fever (oral temperature >= 38 degrees C, or axillary temperature >= 37.5 degrees C; or fever history within 24 hours before baseline, whether taking antipyretics or not; or having fever symptoms within 48 hours before baseline), with or without respiratory symptoms (respiratory rate > 30 beats / min); (2) White blood cell count was normal or low, with or without thrombocytopenia; (3) Chest imaging (chest CT): unilateral or bilateral chest imaging showed multiple (at least 2 lesions) or diffuse patchy or ground glass infiltration (with or without consolidation); 3. SARS-COV-2 is positive for pathogens. After respiratory virus screening, oropharyngeal test pieces with one or mor